Immunovant unveils positive early data for PhII Graves' disease drug

Katherine Lewin

News Reporter

Immunovant’s drug for Graves’ disease showed a response rate that exceeded 50% in an initial cohort of patients in an ongoing 24-week Phase II clinical …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Immunovant unveils positive early data for PhII Graves' disease drug

Katherine Lewin

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Im­muno­vant un­veils pos­i­tive ear­ly da­ta for PhII Graves' dis­ease drug

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Immunovant unveils positive early data for PhII Graves' disease drug